Actualités Bio Rad Laboratories Inc - BIO | Actions New York Stock Exchange

Votre Hub pour des idées et discussions en direct en temps réel

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a...

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its...

Alger Russell Innovation Index Updates for First Quarter 2025

Alger Russell Innovation Index Updates for First Quarter 2025 PR Newswire NEW YORK, March 17, 2025 NEW YORK...

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Transaction To Complement Bio-Rad’s Existing Digital PCR Portfolio and Accelerate Development of Next-Generation Digital PCR Solutions Bio-Rad...

Oncocyte Prices $29.1 Million Equity Offering

Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial LaunchStrategic Partner...

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its...

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Bio-Rad leads investment to support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations...

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad Reports Third-Quarter 2024 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its...

Valerio Therapeutics Annonce ses Résultats Financiers du Premier Semestre 2024 et Fait le point sur ses Activités

Acquisition d'Emglev Therapeutics pour se concentrer sur la découverte d'anticorps à domaine unique (sdAbs) L’essai VIO-01 est actuellement en...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Abonnez-vous à un compte ADVFN en remplissant le formulaire ci-dessous!

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bio Rad Laboratories Inc (BIO)

Votre Hub pour des idées et discussions en direct en temps réel

BIO Actualités

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Alger Russell Innovation Index Updates for First Quarter 2025

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Oncocyte Prices $29.1 Million Equity Offering

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Bio-Rad Reports Third-Quarter 2024 Financial Results

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Valerio Therapeutics Annonce ses Résultats Financiers du Premier Semestre 2024 et Fait le point sur ses Activités

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bio Rad Laboratories Inc (BIO) Actualités

Bio Rad Laboratories Inc (BIO)

Votre Hub pour des idées et discussions en direct en temps réel

BIO Actualités

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Alger Russell Innovation Index Updates for First Quarter 2025

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Oncocyte Prices $29.1 Million Equity Offering

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Bio-Rad Reports Third-Quarter 2024 Financial Results

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Valerio Therapeutics Annonce ses Résultats Financiers du Premier Semestre 2024 et Fait le point sur ses Activités

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Abonnez-vous à un compte ADVFN en remplissant le formulaire ci-dessous!

Supprimer les publicités